Product Description
Mechanisms of Action: TCR Activator
Novel Mechanism: Yes
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bavarian Nordic
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Prostate Cancer
Phase 2: Prostate Cancer|Adenocarcinoma|Vaccinia|Fowlpox
Phase 1: Prostate Cancer|Adenocarcinoma|Vaccinia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03532217 |
CA209-9MW | P1 |
Completed |
Prostate Cancer |
2022-04-01 |
12% |
2022-08-06 |
Primary Endpoints|Study Completion Date |
NCT00096551 |
05-C-0017 | P1 |
Completed |
Prostate Cancer |
2009-12-11 |
2019-03-21 |
||
NCT00113984 |
05-C-0167 | P1 |
Completed |
Prostate Cancer |
2008-02-01 |
2019-03-21 |
Treatments |
|
NCT00001382 |
94-C-0118 | P1 |
Completed |
Prostate Cancer|Adenocarcinoma|Vaccinia |
None |
2024-06-26 |
Treatments |
|
NCT03315871 |
18-C-0005 | P2 |
Completed |
Prostate Cancer |
2024-06-04 |
2025-06-21 |
Primary Endpoints |
|
NCT02772562 |
NCT02772562 | P2 |
Terminated |
Prostate Cancer |
2024-04-29 |
12% |
2025-12-13 |
Primary Endpoints|Treatments|Trial Status |
NCT02933255 |
17-C-0007 | P2 |
Completed |
Prostate Cancer |
2023-06-20 |
2024-06-04 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
NCT02649855 |
16-C-0048 | P2 |
Completed |
Prostate Cancer |
2022-07-01 |
2024-08-07 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04020094 |
AtezoVax | P2 |
Withdrawn |
Prostate Cancer|Adenocarcinoma |
2021-04-09 |
46% |
2021-09-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT02506114 |
NCI-2017-01679 | P2 |
Terminated |
Prostate Cancer |
2020-04-22 |
50% |
2025-08-27 |
Primary Endpoints|Treatments |
NCT01875250 |
13-C-0153 | P2 |
Completed |
Prostate Cancer |
2019-09-01 |
2020-09-17 |
Primary Endpoints|Treatments |
|
NCT02649439 |
16-C-0035 | P2 |
Completed |
Prostate Cancer |
2019-03-28 |
2022-11-15 |
||
NCT02326805 |
NCI-2014-02556 | P2 |
Completed |
Adenocarcinoma|Prostate Cancer |
2018-11-30 |
2023-01-11 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT02153918 |
14-C-0112 | P2 |
Completed |
Prostate Cancer |
2017-07-28 |
2019-03-22 |
Treatments |
|
NCT00450463 |
07-C-0107 | P2 |
Completed |
Prostate Cancer |
2017-04-27 |
2019-03-21 |
Treatments |
|
NCT01145508 |
NCI-2011-02048 | P2 |
Terminated |
Adenocarcinoma|Prostate Cancer |
2012-10-01 |
2019-03-19 |
Treatments |
|
NCT00108732 |
NCI-2012-03075 | P2 |
Completed |
Vaccinia|Fowlpox|Prostate Cancer |
2010-10-01 |
2020-10-26 |
||
NCT00060528 |
03-C-0176 | P2 |
Completed |
Prostate Cancer |
2006-03-07 |
2019-03-21 |
Treatments |
|
NCT00078585 |
TBC-PRO-002 | P2 |
Completed |
Prostate Cancer |
2006-01-04 |
2019-03-21 |
Treatments |
|
NCT01322490 |
Prospect | P3 |
Completed |
Prostate Cancer |
2017-09-25 |
2019-03-22 |
Treatments |
|
2010-021196-85 |
PROSPECT | P3 |
Terminated |
Prostate Cancer |
2017-09-25 |
2022-03-13 |
Treatments |